FK506-binding protein mutational analysis: defining the active-site residue contributions to catalysis and the stability of ligand complexes, Prot Eng, vol.9, pp.173-180, 1996. ,
Two distinct signal transmission pathways in T lymphocytes are inhibited by complexes formed between an immunophilin and either FK506 or rapamycin, Proc Natl Acad Sci U S A, vol.87, pp.9231-9235, 1990. ,
Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes, Cell, vol.66, pp.807-815, 1991. ,
Role of mTOR in anticancer drug resistance: Perspectives for improved drug treatment, Drug Resist Updates, vol.11, pp.63-76, 2008. ,
Immunophilin ligands as a novel treatment for neurological disorders, Trends Pharmacol Sci, vol.21, pp.3-5, 2000. ,
Modeling and synthesis of non-cyclic derivatives of GPI-1046 as potential FKBP ligands with neurotrophic properties, Bioorg Med Chem Lett, vol.16, pp.4385-4390, 2006. ,
Design, synthesis, and kinetic evaluation of high-affinity FKBP ligands and the X-ray crystal structures of their complexes with FKBP12, J Am Chem Soc, vol.115, pp.9925-9938, 1993. ,
Design and structure-based study of new potential FKBP12 inhibitors, Biophys J, vol.85, pp.3194-3201, 2003. ,
Investigating protein-ligand interactions with a mutant FKBP possessing a designed specificity pocket, J Med Chem, vol.43, pp.1135-1142, 2000. ,
Investigations of neurotrophic inhibitors of FK506 binding protein via monte carlo simulations, J Med Chem, vol.41, pp.3928-3939, 1998. ,
Absolute binding free energy calculations using molecular dynamics simulations with restraining potentials, Biophys J, vol.91, pp.2798-2814, 2006. ,
A computational analysis of the binding affinities of FKBP12 inhibitors using the MM-PB/SA method, Proteins Struct Funct Genet, vol.64, pp.1058-1068, 2006. ,
Molecular dynamics simulations of a binding intermediate between FKBP12 and a high-affinity ligand, J Chem Theory Comput, vol.7, pp.725-741, 2011. ,
URL : https://hal.archives-ouvertes.fr/hal-01198467
Tracing kinetic intermediates during ligand binding, J Am Chem Soc, vol.126, pp.9017-9023, 2004. ,
All-atom empirical potential for molecular modeling and dynamics studies of proteins, J Phys Chem B, vol.102, pp.3586-3616, 1998. ,
Classical force field parameters for two high-affinity ligands of FKBP12, J Mol Graph Model, vol.49, pp.118-128, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-01198465
Molecular recognition of protein-ligand complexes: Applications to drug design, Chem Rev, vol.97, pp.1359-1472, 1997. ,
, , 2004.
General atomic and molecular electronic structure system, J Comput Chem, vol.14, pp.1347-1363, 1993. ,
UCSF Chimera-a visualization system for exploratory research and analysis, J Comput Chem, vol.25, pp.1605-1612, 2004. ,
CHARMM: The biomolecular simulation program, J Comput Chem, vol.30, pp.1545-1614, 2009. ,
Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanes, J Comput Phys, vol.23, pp.327-341, 1977. ,
Paul langevin's 1908 paper 'On the theory of brownian motion', Am J Phys, vol.65, pp.1079-1081, 1997. ,
Effective energy function for proteins in solution, Proteins Struct Funct Genet, vol.35, pp.133-152, 1999. ,
Structural coupling between FKBP12 and buried water, Proteins Struct Funct Bioinf, vol.74, pp.603-611, 2009. ,
Atomic structures of the human immunophilin FKBP12 complexes with FK506 and rapamycin, J Mol Biol, vol.229, pp.105-124, 1993. ,
Stochastic boundary conditions for molecular dynamics simulations of ST2 water, Chem Phys Lett, vol.105, pp.495-500, 1984. ,
Forces and energetics of hapten-antibody dissociation: a biased molecular dynamics simulation study, J Mol Biol, vol.314, pp.589-605, 2001. ,
MD simulation of protein-ligand interaction: formation and dissociation of an insulin-phenol complex, Biophys J, vol.84, pp.1493-1506, 2003. ,
Comparison of three perturbation molecular dynamics methods for modeling conformational transitions, J Chem Theory Comput, vol.5, pp.1304-1314, 2009. ,
Change of the unbinding mechanism upon a mutation: A molecular dynamics study of an antibody-hapten complex, Protein Sci, vol.14, pp.2499-2514, 2005. ,
Molecular dynamics simulation of the unfolding of barnase: characterization of the major intermediate, J Mol Biol, vol.275, pp.677-694, 1998. ,
Computational analysis of chain flexibility and fluctuations in Rhizomucor miehei lipase, Prot Eng, vol.12, pp.747-754, 1999. ,
Crystal structure of bacteriophage T4 deoxynucleotide kinase with its substrates dGMP and ATP, EMBO J, vol.15, pp.3487-3497, 1996. ,
HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations, Proc Natl Acad Sci U S A, vol.103, pp.915-920, 2006. ,
X-ray structures of small ligand-FKBP complexe provide an estimate for hydrophobic interaction energies, J Mol Biol, vol.295, pp.953-962, 2000. ,
Activation of an inactive immunophilin by mutagenesis, J Am Chem Soc, vol.115, pp.821-822, 1993. ,
Modeling the interaction between FK506 and FKBP12: a mechanism for formation of the calcineurin inhibitory complex, Bioorg Med Chem Lett, vol.5, pp.211-232, 1997. ,
Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin, Acta Cryst, vol.51, pp.511-521, 1995. ,
The importance of being Tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins, ACS Chem Biol, vol.4, pp.325-334, 2009. ,
Entropic contributions and the influence of the hydrophobic environment in promiscuous protein-protein association, Proc Natl Acad Sci U S A, vol.105, pp.7456-7461, 2008. ,
Rapid protein ligand docking using soft modes from molecular dynamics simulations to account for protein, Proteins Struct Funct Genet, vol.54, pp.759-767, 2004. ,
Solution structure of FKBP, a rotamase enzyme and receptor for FK506 and rapamycin, Science, vol.252, pp.836-839, 1991. ,
Natural products as probes of cellular function: studies of immunophilins, Angew Chem Int Ed, vol.31, pp.384-400, 1992. ,
, Int J Biochem Cell Biol, vol.52, pp.42-47, 2005.
FKBP12-binding domain analogues of FK506 are potent, nonimmunosuppressive neurotrophic agents in vitro and promote recovery in a mouse model of Parkinson's disease, Bioorg Med Chem Lett, vol.7, pp.1785-1790, 1997. ,